Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year

Reuters03-11 23:45

Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year

Regenxbio reported interim data from the Phase I/II AFFINITY DUCHENNE trial evaluating RGX-202 for Duchenne muscular dystrophy, and the results were presented by Carolina Tesi-Rocha at the MDA Clinical and Scientific Conference. In seven participants treated at 2x10^14 GC/kg, NSAA improved by 5 points versus the cTAP model at 1 year. Cardiac MRI measures in these seven participants showed left ventricular ejection fraction of 62% at baseline and 62% at 12 months. In biomarker analyses (n=13), an additional patient had microdystrophin expression of 51% at Week 12, and the pivotal phase primary endpoint is the proportion of participants with expression above 10% at Week 12. Regenxbio said pivotal topline data are expected in early Q2 2026, with a pre-BLA meeting request planned for mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603111145PR_NEWS_USPR_____PH07897) on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618292389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 23:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618292389","market":"nz","top_or_hot":-1,"title":"Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Regenxbio reported interim data from the Phase I/II AFFINITY DUCHENNE trial evaluating RGX-202 for Duchenne muscular dystrophy, and the results were presented by Carolina Tesi-Rocha at the MDA Clinical and Scientific Conference. In seven participants treated at 2x10^14 GC/kg, NSAA improved by 5 points versus the cTAP model at 1 year. Cardiac MRI measures in these seven participants showed left ventricular ejection fraction of 62% at baseline and 62% at 12 months. In biomarker analyses (n=13), an additional patient had microdystrophin expression of 51% at Week 12, and the pivotal phase primary endpoint is the proportion of participants with expression above 10% at Week 12. Regenxbio said pivotal topline data are expected in early <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, with a pre-BLA meeting request planned for mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603111145PR_NEWS_USPR_____PH07897) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-11 23:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Regenxbio reported interim data from the Phase I/II AFFINITY DUCHENNE trial evaluating RGX-202 for Duchenne muscular dystrophy, and the results were presented by Carolina Tesi-Rocha at the MDA Clinical and Scientific Conference. In seven participants treated at 2x10^14 GC/kg, NSAA improved by 5 points versus the cTAP model at 1 year. Cardiac MRI measures in these seven participants showed left ventricular ejection fraction of 62% at baseline and 62% at 12 months. In biomarker analyses (n=13), an additional patient had microdystrophin expression of 51% at Week 12, and the pivotal phase primary endpoint is the proportion of participants with expression above 10% at Week 12. Regenxbio said pivotal topline data are expected in early <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, with a pre-BLA meeting request planned for mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603111145PR_NEWS_USPR_____PH07897) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL5jr5ct:1","article_id":"2618292389","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618292389","pubTimestamp":1773243936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Regenxbio reported interim data from the Phase I/II AFFINITY DUCHENNE trial evaluating RGX-202 for Duchenne muscular dystrophy, and the results were presented by Carolina Tesi-Rocha at the MDA Clinical and Scientific Conference. In seven participants treated at 2x10^14 GC/kg, NSAA improved by 5 points versus the cTAP model at 1 year. Cardiac MRI measures in these seven participants showed left ventricular ejection fraction of 62% at baseline and 62% at 12 months. In biomarker analyses , an additional patient had microdystrophin expression of 51% at Week 12, and the pivotal phase primary endpoint is the proportion of participants with expression above 10% at Week 12. Regenxbio said pivotal topline data are expected in early Q2 2026, with a pre-BLA meeting request planned for mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4505":"高瓴资本持仓","RGNX":"Regenxbio Inc","BK4139":"生物科技"},"translate_title":"Regenxbio报告I/II期亲和力DUCHENNE中期RGX-202数据，NSAA在1年时上升5个百分点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGNX":0.9},"content_text":"Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year\n    \n\n        Regenxbio reported interim data from the Phase I/II AFFINITY DUCHENNE trial evaluating RGX-202 for Duchenne muscular dystrophy, and the results were presented by Carolina Tesi-Rocha at the MDA Clinical and Scientific Conference. In seven participants treated at 2x10^14 GC/kg, NSAA improved by 5 points versus the cTAP model at 1 year. Cardiac MRI measures in these seven participants showed left ventricular ejection fraction of 62% at baseline and 62% at 12 months. In biomarker analyses (n=13), an additional patient had microdystrophin expression of 51% at Week 12, and the pivotal phase primary endpoint is the proportion of participants with expression above 10% at Week 12. Regenxbio said pivotal topline data are expected in early Q2 2026, with a pre-BLA meeting request planned for mid-2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603111145PR_NEWS_USPR_____PH07897) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618292389","isCrawlerRequest":true}